WASHINGTON, DC: The Dome of the U.S. Capitol Building is visible as a visitor stands with his bicycle on the grounds of Capitol Hill on January 2, 2025. (Photo by Andrew Harnik/Getty Images) PBMs, the ...
Compensation reforms prohibit price- or rebate-linked PBM revenue in Part D, pushing flat service-fee models and broadly capturing affiliates such as rebate GPOs and aggregators. Reform priorities aim ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. If you’re frustrated with your pharmacy benefit manager ...
In 2025, the three largest pharmacy benefit managers are largely rejecting biosimilars from their formularies, with the exception of their own private-label medicines, Drug Channels reported Jan. 22.
Alternative pharmacy benefit manager Serve You Rx is seeking to generate additional savings for its clients by adding two biosimilars for the popular drug Stelara to its formulary. The PBM will add ...
Medicare Part D PBM compensation shifts to flat administrative fees, aiming to reduce incentives that favor higher-list-price products driven by rebate maximization. Mandatory 100% pass-through of ...
Nearly 2 years after entering the market, adalimumab biosimilars are finally seeing traction. CVS Health’s Caremark, Cigna’s Express Scripts, and UnitedHealth Group’s OptumRx, which are pharmacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results